Volpara Healh Technologies Announces VolparaDensity Selected for Inclusion in Latest Tyrer-Cuzick Breast Cancer Risk Assessment Tool
Widely recognised by clinicians and payors worldwide, the Tyrer-Cuzick Risk Assessment Tool now includes breast density alongside family history and genetic factors to aid decision-making process regarding breast cancer screening.
“This is a major validation of Volpara’s technology. It is the only commercial density score that has been selected for inclusion into the Tool,” Dr Ralph Highnam, CEO of Volpara Health Technologies.
Wellington, NZ, 14th November 2016: Volpara Health Technologies (“Volpara”; ASX:VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, has today announced that breast density measurements generated by its VolparaDensity software have been incorporated into the latest version of the Tyrer-Cuzick Breast Cancer Risk Assessment Tool. Despite being recognised as a major independent risk factor for cancer, this is the first time breast density has been included in a major, widely accepted breast cancer risk model.
For further information please download PDF attached:
Download this document
